Hypomethylating agents in the treatment of chronic myelomonocytic leukemia: a meta-analysis and systematic review. Issue 1 (1st January 2021)

• Record Type: Journal Article
• Authors: Xu, Ruohao; Li, Minming; Wu, Ping; Deng, Chengxin; Geng, Suxia; Huang, Xin; Weng, Jianyu; Du, Xin
• Is Part Of: Hematology. Volume 26:Issue 1(2021)
• Page Start: 312
• Page End: 320
• Publication Date: 2021-01-01
• Subjects: Decitabine -- azacitidine -- chronic myelomonocytic leukemia -- hypomethylating agents -- meta-analysis -- cohort study -- adverse events -- preditive factors; Blood -- Diseases -- Periodicals; Hematology -- Periodicals; Blood -- Transfusion -- Periodicals; 616.15005
• DOI: 10.1080/16078454.2021.1875600
• Languages: English
• ISSNs: 1024-5332

Abstract

ABSTRACT: Objectives: The present meta-analysis was performed to evaluate the efficacy, toxicities of both hypomethylating agents (decitabine and azaciticine) in the treatment of CMML patients. Methods: All available cohort studies of patients with CMML treated with decitabine and azacitidine were identified. The primary endpoints of this meta-analysis were response to hypomethylating agents. Pooled estimates of treatment response and drug-related adverse events were calculated using fixed or random effect models. Results: Fourteen studies with 600 CMML patients (decitabine: n=196; azacitidine: n=404) were identified and included for meta-analysis. HMAs yielded a pooled ORR estimate of 43% (95% CI: 36%-50%) in patients with CMML. Patients received either azacitidine or decitabine exhibited comparable incidence of ORR (43% vs. 45%, P=0.810), while significantly higher incidence of mCR was observed in patients treated with decitabine (23% vs. 10%, P=0.000). Decitabine treatment was also associated with higher incidence of transfusion independence (42% vs. 20%, P=0.044). Both HMAs led to objective hematologic or non-hematologic AEs (27%-43%), while dosage modification/delay were more frequent in patients treated with azacitidine (81% vs. 67%, P=0.021). Conclusion: This current study may provide preliminary data in evaluating the efficacy and safety of HMAs in patients with CMML. Decitabine and azacitidine are comparable effective and safe in treating CMML. However, it is necessary to point out that any comparison of decitabine and azacitidine with respect to clinical outcomes can only be done in the context of a randomized controlled trial.